1. Amplatzer Occluders for Effective Nonsurgical Management of Bronchopleural Fistulae.
- Author
-
Gershman E, Azem K, Heesen P, Pertzov B, Rosengarten D, Bruckheimer E, Peysakhovich Y, and Kramer MR
- Subjects
- Humans, Middle Aged, Male, Retrospective Studies, Female, Aged, Treatment Outcome, Pneumonectomy adverse effects, Bronchoscopy, Bronchial Fistula therapy, Bronchial Fistula surgery, Pleural Diseases therapy, Pleural Diseases surgery, Septal Occluder Device
- Abstract
Background: To assess the safety and efficacy of bronchopleural fistulae closure with Amplatzer occluder devices (AGA Medical, Golden Valley, MN) through our experience of over 14 years., Methods: Retrospective data review of patients from Rabin Medical Center who underwent Amplatzer occluder device placement between March 2007 and September 2021 for bronchopleural fistulae closure., Results: In total, 72 patients had 83 Amplatzer occluder devices implanted for bronchopleural fistulae closure. The median age was 65.5 (interquartile range 56.0-72.3) years. The primary diseases were lung malignancy (48 [66.7%]) and thoracic infection (9 [12.5%]). Bronchopleural fistulae developed mainly following pneumonectomy (40.3%) and lobectomy (33.3%), with a median time from surgery to Amplatzer placement of 3.9 (interquartile range 1.4-16.4) months. We encountered no procedural or immediate postprocedural complications or deaths. Six months after Amplatzer insertion, there were 7 (8.4%) Amplatzer removals and 11 (15.3%) fistula-related deaths., Conclusions: Amplatzer occluders are a safe modality for nonsurgical bronchopleural fistulae management with ease of placement under moderate sedation and flexible bronchoscopy with good short- and long-term effectivity., (Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF